Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and Beyond

The blood–brain barrier permeant, copper-containing compound, Cu(II)(atsm), has successfully progressed from fundamental research outcomes in the laboratory through to phase 2/3 clinical assessment in patients with the highly aggressive and fatal neurodegenerative condition of amyotrophic lateral sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikseresht, Sara, Hilton, James B.W., Kysenius, Kai, Liddell, Jeffrey R., Crouch, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694234/
https://www.ncbi.nlm.nih.gov/pubmed/33158182
http://dx.doi.org/10.3390/life10110271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694234/
https://www.ncbi.nlm.nih.gov/pubmed/33158182
http://dx.doi.org/10.3390/life10110271

Ejemplares similares